Close

Jefferies Predicts Stellar Outlook For Medivation Inc (MDVN) and MDV3100

April 25, 2012 9:39 AM EDT
Get Alerts MDVN Hot Sheet
Price: $81.44 --0%

Rating Summary:
    12 Buy, 17 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 2 | New: 35
Join SI Premium – FREE
Today Jefferies analysts increased their price target on Medivation, Inc’s (NASAQ: MDVN) from $95 to $97 based on expectation that their cancer drug MDV3100 will reach $2 billion in sales by 2020.

Jefferies analysts are optimistic that drug will continue to do will in clinical trails. MDV3100 has shown positive results in a Phase III trail (AFFIRM) for post-cehmotherapy castrate-resistant prostate cancer (CRPC), and is currently in Phase III (PREVAIL).

Jefferies analysts conducted a proprietary survey involving urologists and oncologists showing strong MDV3100 pre and post-chemo uptake.

Jefferies has a BUY rating Medivation (NASDAQ: MDVN).

For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

Shares of Medivation closed at $74.82 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co